Schroder UK Public Private Tst plc Investment in Araris (5495E)
28 Octubre 2022 - 10:29AM
UK Regulatory
TIDMSUPP
RNS Number : 5495E
Schroder UK Public Private Tst plc
28 October 2022
28 October 2022
Schroder UK Public Private Trust plc
Investment in Araris
Schroder UK Public Private Trust plc (the "Company") is pleased
to announce it has made a commitment of CHF 3 million (GBP2.7
million) to antibody-drug conjugates (ADCs) development company,
Araris Biotech AG ("Araris"), as part of its CHF 23.5 million
(GBP21.4 million) financing round. New investors Wille Finance (CH)
and Institute for Follicular Lymphoma Innovation (US) as well as
existing investors in the company's blue chip syndicate
participated in this financing including Pureos Bioventures, 4BIO
Capital, VI Partners, btov Partners and Redalpine.
Araris is pioneering the development of a novel antibody-drug
conjugate (ADC)-linker technology to enable efficient and precise
production of ADCs. Its linker platform enables the attachment of
any drug payload to 'off the shelf' antibodies, without the need
for prior antibody engineering. The resulting ADCs have shown very
high activity at low doses and an improved therapeutic index
compared to FDA-approved ADCs. Araris is a spin-off company from
the Paul Scherrer Institute (PSI) and ETH Zurich.
The Company is committed to improving its sustainability profile
and intends to disclose, where appropriate, the United Nations'
Sustainable Development Goals ("SDGs") associated with new
investments. The investment in Araris is in line with SDG 3 "Good
health and well-being", specifically Target 3.4 "Reduce mortality
from non-communicable diseases and promote mental health" and
Target 3.B "Support research, development and universal access to
affordable vaccines and medicines".
Tim Creed and Roger Doig, Portfolio Managers of the Company,
jointly commented: "Araris is the tenth new investment and the
second therapeutics focused private equity investment since our
appointment as Portfolio Manager. This investment is in line with
the Company's private equity sub-strategy for backing innovative
life sciences businesses, at the clinical or near-clinical stage,
with high quality science, a strong financing position, alongside
high-quality co-investors."
Enquiries:
Schroder Investment Management Limited
Augustine Chipungu (Press) 0207 658 2106
John Spedding 0207 658 3206
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMPBATMTTTBAT
(END) Dow Jones Newswires
October 28, 2022 11:29 ET (15:29 GMT)
Woodford Patient Capital (LSE:WPCT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Woodford Patient Capital (LSE:WPCT)
Gráfica de Acción Histórica
De May 2023 a May 2024
